The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S23-S27, November 2004

EXPRESSION OF GENES AND PROTEINS SPECIFIC FOR PROSTATE CANCER

  • EDWARD P. GELMANN

      Affiliations

    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Oncology, Lombardi Cancer Center, Georgetown University, 3800 Reservoir Rd., Northwest, Washington, D. C. 20057 (telephone: 202-444-2207; FAX: 202-444-1229)
  • ,
  • O. JOHN SEMMES

From the Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, D. C., and Virginia Prostate Center, Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia

ABSTRACT 

Purpose

We reviewed the pertinent literature and discuss high throughput approaches to the identification of molecular markers characteristic of prostate cancer.

Materials and Methods

A PubMed search was performed for expression array studies comparing prostate cancer tissues with nonmalignant tissues and serum proteomic studies comparing patients with prostate cancer and controls.

Results

The expression of several genes may help distinguish prostate cancer cells from nonmalignant prostatic epithelial cells. A few genes, such as those coding for hepsin, LIM protein and α-methylacyl-coenzyme A racemase, have consistently been identified as being over expressed in cancer cells compared with nonmalignant cells. Proteomic analysis using mass spectroscopy has identified spectral patterns that have a significant correlation with the presence of prostate cancer. The optimal presentation of the spectra may depend highly on technical factors and experimental protocols have yet to be standardized among laboratories. Moreover, to our knowledge the serum proteins that comprise the mass spectral patterns of prostate cancer have yet to be identified.

Conclusions

High throughput techniques have the potential to aid in prostate cancer diagnosis, early detection and developmental therapies. Markers with the potential to aid in diagnosis have been identified and targets for imaging or therapeutic approaches appear to be at hand. Mass spectral analysis of serum is in the early stages and it requires standardization of technical parameters among laboratories. In addition, the identification of target proteins will contribute to ease of detection and cross-laboratory verification.

Key Words::  prostate , prostatic neoplasms , gene expression , tumor markers, biological

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by National Institutes of Health Grants ES09888 and CA96854 (EPG) and CA85067-05 (OJS).

PII: S0022-5347(05)61303-1

doi:10.1097/01.ju.0000141781.70474.48

The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S23-S27, November 2004